Analyst coverage of this micro-cap is limited. Two firms maintain clearly dated, current price targets. Lake Street Capital Markets (analyst Ryan Meyers) carries a Buy rating with a $7.00 target, cut from $17.00 on October 20, 2026 after the company reported "mixed" preliminary third-quarter results. ATB Capital Markets maintains a Buy rating with a $12.00 target, also reduced from $16.00 on the same date. The arithmetic mean of these two verified targets is $9.50, which serves as the central target in this article, with an approximate low-to-high range of $7.00 to $12.00.
Both firms remain constructive on the longer-term story but acknowledge near-term pressure. Lake Street's original July initiation argued that Q1 2026 marked an earnings trough, with production expected to scale from roughly 666,000 pounds in 2025 toward one million pounds in 2026 and cost per pound falling toward a $95 quarterly target in the second half of 2026. The subsequent target cuts reflect softer realized pricing, unfavorable product mix, and a more gradual margin recovery than initially modeled. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The latest verified price is approximately $1.29, near the low end of a 52-week range of $1.06 to $13.93 and down sharply from the prior month. Reaching $9.50 implies upside of roughly 636%, which must be characterized as a very large move. Because the stock has already fallen more than 90% from its highs, a meaningful portion of that percentage gap reflects how depressed the share price has become, rather than an inherently inflated target.
The company generates trailing revenue of roughly $177 million but reported a net loss of about $64 million over the same period, with diluted EPS (earnings per share) of approximately -$0.74. It trades near 0.7 times trailing sales, a level that prices in significant distress. Any credible path toward the target would require a sustained recovery in wholesale biomass pricing, successful execution of the production ramp, and a return to positive operating cash flow.
The stock is trading just above its 52-week low of $1.06 after a collapse from the $13.93 high, a move of roughly 90%. The prior high now acts as a distant overhead reference rather than a near-term obstacle. Psychologically, reclaiming the $2 and then $5 levels would represent early steps, while the $7.00 analyst target coincides with the lowest published objective and could function as a resistance level if approached. The dominant structure remains a sharp downtrend, and no confirmed bottoming pattern has yet emerged.
Analyst price targets typically reflect a roughly 12-month research horizon, though neither firm has published a precise timeframe for these specific objectives. Investors should monitor quarterly earnings and guidance, particularly wholesale biomass pricing and cost-per-pound trends, any capital-raising announcements, California regulatory and tax developments, and progress on the production ramp. A stabilization or recovery in the broader U.S. cannabis sector would also be a key input to the price forecast.
The $9.50 central target—the average of the two verified analyst price targets—sits far above the current price of about $1.29 and implies an enormous, roughly 636% move. The bullish case rests on Glass House's genuine cost advantages and an eventual margin recovery, but the near-term picture is defined by falling prices, negative earnings, downward estimate revisions, and a fragile balance sheet. The wide $7.00-to-$12.00 range and the steep recent target cuts illustrate how uncertain the recovery path remains. Investors should weigh the stock's distressed valuation against execution and liquidity risks, and watch the upcoming earnings, pricing, and capital-structure developments closely before drawing any conclusion about whether this target is attainable.
For traders who prefer a systematic approach to volatile names like GLAS, Tickeron's AI Daily Buy/Sell Signals offer a data-driven complement to manual research. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. This can help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than scanning charts by hand. I find these signals particularly useful when reviewing names with thin coverage like this one.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where GLAS advanced for three days, in 199 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for GLAS just turned positive on October 28, 2026. Looking at past instances where GLAS's MACD turned positive, the stock continued to rise in 26 of 36 cases over the following month. The odds of a continued upward trend are 72%.
GLAS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GLAS as a result. In 72 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLAS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for GLAS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.699) is normal, around the industry mean (6.379). P/E Ratio (-2.737) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.880) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. GLAS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLAS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsGeneric